Senti Biosciences Holdings Inc Dossier
Qualitative Analysis
Business overview
Senti Biosciences Holdings, Inc. (formerly Senti Biosciences, Inc.) is a clinical-stage biotechnology company specializing in the development of next-generation cell and gene therapies. The company's proprietary synthetic biology platform is designed to engineer Gene Circuits into cellular medicines, providing enhanced precision, control, and logic-gated decision-making capabilities. Its lead clinical candidate, SENTI-202, is a first-in-class, logic-gated (OR+NOT), off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), while sparing healthy bone marrow cells.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing the clinical development of SENTI-202, a potentially first-in-class, off-the-shelf Logic Gated CAR-NK cell therapy designed to selectively target CD33 and/or FLT3 expressing hematologic malignancies while sparing healthy bone marrow.
Expected impact: Establish a registrational pathway for a first-in-class allogeneic treatment for AML and myelodysplastic syndrome (MDS).
Streamlining operations and executing lease modifications, including amendments to the Alameda facility lease, to significantly reduce ongoing operating cash burn.
Expected impact: Substantially lowered quarterly R&D and G&A cash expenses, narrowing net losses and optimizing capital allocation toward clinical programs.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides critical capital to extend the company's cash runway and outlines a potential holding company merger that could grant Celadon majority control (approx. 54.6%) and establish a CVR structure.
Terms: Up to $40.0 million in senior secured convertible notes (initial $10.0 million tranche closed in May 2026; second $30.0 million tranche optional). Includes a potential CVR paying up to $60.0 million in cash upon specified SENTI-202 milestones.
Supports the clinical development and evaluation of SENTI-301A for the treatment of advanced glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC) in China.
Terms: Senti Bio is eligible to receive clinical, regulatory, and commercial milestone payments, plus royalties on net sales in the territory.
Collaborative development of next-generation gene therapies utilizing Senti Bio's proprietary Gene Circuit platform to design cell-type-specific AAV vectors.
Terms: Includes upfront payments, research funding, and potential future milestone and royalty payments.
Focuses on applying Senti Bio's Gene Circuit technology to discover and develop cell therapies in regenerative medicine.
Terms: Senti Bio received upfront option fees and is eligible for future development, regulatory, and commercial milestone payments.